click below
click below
Normal Size Small Size show me how
Carroll U Pharm 1
Stack #147067
Question | Answer |
---|---|
Effectiveness | elicits responses for which it has been administered. |
Safety | drug does not produce a harmful effect over extended period of time. |
Selectivity | elicits only those responses for which it is given, not such thing. |
Pharmacokinetics | study of drug absorption, distribution in the body, metabolism in the liver and kidneys, and excretion. |
Pharmacodynamics | study of a drug at the site of action and the EFFECT ON THE BODY. |
Toxicology | study of harmful effects of chemicals including drugs, environment toxins, and poisons. |
Graded Dose Respose Curve | *for 1 patient, used to determine the EC50 which is the dose in a patient that will result in half the EMax. |
Potency | the more potent the drug requires lower dose to produce the same effect as a higher dose of a second drug, **determined by affinity for its receptor and the ability of the drug to reach its site of action., Only in 1 patient. |
Efficacy | determined by type of interaction with receptor, and limitations on amount that can be administered, |
EMax. | = max effect produced |
Quantal Dose Response Curve | biological variability among people/populations, graphs Y |
Hyperreactive | Pt. need a very low dose before a response is seen. |
Hyopreactive | Pt. need very high does before a response is seen. |
Tolerance | Time related loss of resonse to a drug (weeks to months) |
Idiosyncratic drug response | infrequently observed drug effect. Ex: 1 out of 300,000 people have some side effect. |
Tachyphylaxis | Tolerance that happens very quickly (minutes to hours) |
Hypersensitivity | allergic reaction to a drug. |
Therapeutic Index | TD50/ED50 TD50=median toxic dose 50% of pop. exhibits adverse effects ED50= median effective dose 50% pop. responds in a specified manner. Indicator of drug safety, the greater the TI, the safer the drug. |
Bioavailability | extent to which the drug reaches systemic circulation, get first pass effect of given orally, 100% if IV |
Volume of Distribution | body space into which a drug can diffuse Ex: asprin only in bloodstream Vd=8.4L |
Clearance | amount of blood or other fluids from which all drug is removed per unit time (steady state concentrations) |
Half Life | dosing regimen to achieve steady state concentration of drug in blood, take half life x 4 |
Absorption | dependent on: administration mode, product chemistry, disease state, drug interactions, first pass effect, and pH |
Distribution | dependent on: drug charac's (lipid soluble, size, ionized), binding to plasma protein (only free drug can be transported), blood flow to tissues absent in abscesses or tumors, BBB, pass b/w capillaries |
Metabolism | Phase I |
Elimination | Filtration( protein binding, molecular size and charge), passive transport (dependent on pH & lipid solubility), active transport (requires ATP) |
Receptors | proteins with unique binding sites inside cell or on surface, interact w/ endogenous and exogenous cmpds, interpret a signal from the drug and transfer that info into effect, middle man b/w drug and body. |
Signal Transduction | 1.ligand binds to the receptor 2. receptor propagates a signal 3. proteins are turned on and mobilize 2nd messanger molecules to amplify signal 4. 2nd messangers active other proteins that carry the signal further 5. physiological response 6. termination |
Second Messengers | take an external stimulus and turn it into a cellular response and allow for quick movement of a signal. |
Drug Selectivity | related to both affinity and efficact, influences only 1 particular tissue and induces a specific response, side effects. |
Affinity | refers to the attraction between a receptor and ligand. |
Efficacy | refers to the ability of a ligand to bind to the receptr, activate it, and lead to some physiological response. |
Agonist | a drug that binds to the receptor and causes a response |
Antagonist | a drug that binds to the receptor without a response, BLOCKER! |